CME
Comparing In-hospital Mortality With Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate
July 28, 2023
Host: Gregory J. Fermann, MD Patients presenting to the hospital with severe bleeding and underlying treatment with Factor Xa (FXa) or Factor IIa inhibitors represent an enormous challenge to providers and clinicians since the approvals of apixa
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!